For pharmaceuticals, current regulatory guidance for photosafety testing states that studies are warranted for drug candidates that both absorb light in the range of 290-700 nm and that are either applied topically or reach the skin or eyes by systemic exposure. In contrast to standard genotoxicity evaluations, where a positive (or equivocal) result in vitro can be placed into context with additional testing in vivo, there are no equivalent short-term in vivo photogenotoxicity assays in the current photosafety test battery. Therefore, a short-term in vivo assay for the evaluation of a photogenotoxic potential in the skin, the target organ for photocarcinogenicity, was developed in rats. After oral 8-methoxypsoralen administration, rats were exposed to ultraviolet radiation and sacrificed 3 days after treatment to isolate epidermal cells for subsequent micronucleus (MN) evaluation. Optimal conditions were determined to obtain maximal induction of MN, followed by demonstrating feasibility and reproducibility of the method. The results of the present study indicate that the in vivo rat skin photomicronucleus test may be a promising tool for detection of photoclastogenicity. Given the association between MN induction and cancer, the assay may also provide a promising tool for the early detection of photocarcinogenesis and help bridge the gap in the existing photosafety testing paradigm.
Introduction
It is well known that chemical photoactivation following the absorption of solar ultraviolet radiation (UVR) may result in the formation of reactive intermediates or the release of various reactive oxygen species, which can interact with biological systems and ultimately lead to cellular cytotoxicity and/or DNA damage (i.e. phototoxicity and/or photogenotoxicity) and if prolonged, photoinduced ageing or photocarcinogenicity (1) (2) (3) . As a result, photosafety testing has become a mandatory regulatory requirement for medicinal and consumer products, which meet the designated triggers for absorbance, tissue distribution or photoinstability. Testing may include an assessment of acute phototoxicity (photoirritation), photoallergy, photogenotoxicity and photocarcinogenicity (4) .
In the European Union (EU), the conditions for the photosafety evaluation of pharmaceuticals and personal consumer products are described by the European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products (CPMP) 'Notes for Guidance on Photosafety Testing' (5) or the 'Notes of Guidance of the EU Scientific Committee on Cosmetics and Non-Food Products' (6), respectively. Both of these documents provide guidance on the strategy and approaches that should be adopted by manufacturers for evaluating the photosafety of products prior to review by regulatory authorities. In the USA, the Federal Drugs Agency (FDA) Center for Drug Evaluation and Research also published a guidance for industry on photosafety testing (7) .
For pharmaceuticals, current regulatory guidance for photosafety testing states that studies are warranted for drug candidates that both absorb light in the range of 290-700 nm and that are either applied topically or reach (EMEA)/ 'significantly partition to' (FDA) the skin or eyes via oral exposure (5, 7) . Where considered necessary, a tiered approach to photosafety testing is recommended, which includes an acute assessment of phototoxicity in vitro for hazard identification prior to in vivo assessments for risk characterization. The 3T3 neutral red uptake phototoxicity assay is recommended by the Organisation for Economic Co-operation and Development (OECD) and CPMP for hazard identification and guidelines have been published (5, 8) .
In terms of photogenotoxicity testing, the main objective is an assessment of the potential of a compound to be converted into a photochemical carcinogen upon activation with ultraviolet (UV) and/or visible (sic solar simulated) radiation. Several in vitro photogenotoxicity assays, such as the photoAmes, photochromosomal aberration and photocomet assays, have been described in the literature and are based on standard 'dark' versions of regulatory assays used for genotoxicity assessment (for reviews, see 9, 10) . The EMEA CPMP 'Notes for Guidance on Photosafety Testing' recommend photoclastogenicity testing [in vitro chromosomal aberration or micronucleus test (MNT)] in the first instance as there are no genotoxic photochemicals that are exclusively mutagenic and because photochemical reaction mechanisms are in the main strongly clastogenic. Compounds producing positive and/or unequivocal results in these in vitro photogenotoxicity assays should be confirmed by in vivo photocarcinogenicity studies (5) or assumed to be photocarcinogenic. However, oversensitivity and the occurrence of 'pseudoeffects' (i.e. increased sensitivity of the test system by UV irradiation) with in vitro photogenotoxicity assays (11, 12) , in particular, the mammalian cell test for photogenotoxicity have become a major problem as described in the 'Concept Paper on the Need for Revision of the Note for Guidance on Photosafety Testing' (13) , and consequently, the number of false positives and unnecessary in vivo photocarcinogenicity studies will increase.
In contrast to standard genotoxicity evaluations, where a positive (or equivocal) result in vitro can be placed into context with additional testing in vivo, there are no equivalent short-term in vivo photogenotoxicity assays in the current photosafety test battery. This is clearly an important gap in the safety evaluation of compounds, resulting is a significant shortfall in any risk assessment of potential photogenotoxic liabilities. Moreover, the absence of a standard photogenotoxicity assay presents a significant deficit in the scientific understanding of the relationship between photogenotoxicity and photocarcinogenicity. The development, therefore, of a short-term in vivo assay for the evaluation of a photogenotoxic potential in skin, the target organ for photocarcinogenicity, is viewed as a high priority. Since an in vivo negative result would most likely discharge the risk for photocarcinogenicity, this would avoid costly and time-consuming photocarcinogenicity testing in vivo and thereby lead to a reduction in animal numbers. The additional benefit of an in vivo assay would be that data are more applicable to human risk assessment since in vitro assays mainly identify hazard. There are only a handful of reports of photoadapted in vivo genotoxicity assays published, such as in vivo photocomet assays in skin of rats and mice (14, 15) and the in vivo skin photoMNT in mice (16, 17) .
The development of an in vivo rat skin MNT has been described by Nishikawa et al. (18, 19) following topical treatment with several known genotoxic compounds. Based on these reports, the purpose of the present paper is to describe the development and optimization of a rat epidermal photoMNT. As part of the assay development, various parameters were considered, including selection of UV irradiation modality and dose, optimization of dorsal skin sampling procedures and harvest time after irradiation for maximal MN frequencies, and comparison of irradiated dorsal skin samples with nonirradiated ventral skin samples to determine whether the latter could be used as an internal negative control (and therefore reduce the number of animals needed per experiment). In addition, 8-methoxypsoralen (8-MOP) treatments have been characterized in the assay for use as a putative positive control. As part of the characterization, pharmacokinetic parameters were investigated along with clinical observations and histopathological changes in the skin. Finally, the reproducibility of the in vivo skin photoMNT was determined in repeated studies using 8-MOP.
Materials and methods

Chemicals
Minimal essential medium (MEM), phosphate-buffered saline (PBS) and trypsin solution (0.25%) were from Gibco Invitrogen Incorporated, Paisley, Scotland. Foetal calf serum (FCS) was from BioWhitaker, Walkersville, Maryland, USA. 8-MOP, acridine orange solution, ethylenediaminetetraacetic acid and potassium chloride (KCl) were from Sigma, St Louis, Missouri, USA. Ethanol and glacial acetic acid were from Merck, Darmstadt, Germany. Methanol was from Biosolve, Valkenswaard, The Netherlands. 
Animals and treatments
Male Sprague-Dawley (SD) rats (Charles River, Sulzfield, Germany), 8-to 10-week old (body weight $300 g), were kept in standard conditions: 12-h yellow light/dark cycle (yellow light was used to avoid possible increase in background MN formation by standard electronic light), 22 AE 2°C, 40-70% humidity and 10 air changes/h. Rats were fed on a standard laboratory diet (Special Diets Services). Each batch of this diet was analysed by the supplier for nutrients and contaminants. Tap water was of drinking quality. Access to food and water was ad libitum. Typically, five animals per treatment group were used, unless otherwise stated. Ethical use of animals and animal welfare was approved by the Dutch animal experimental committee.
The dorsal area ($6 Â 8 cm) of each rat was shaved prior to irradiation and/ or dosing to remove as much fur as possible. When treated dermally, animals were administered 240 ll of vehicle (50% aqueous ethanol) or 8-MOP (60 lg/ ml, corresponding to a 8-MOP dose of 0.9 lg/cm 2 ), followed by UV irradiation. When orally treated, rats were dosed, by gavage, with vehicle control (corn oil) or 8-MOP (10-400 mg/kg bw) in an administration volume of 10 ml/kg bw, followed by UV irradiation. Assay optimization studies using 8-MOP are described below.
Irradiation
Animals were placed under a grid in macrocolon cages to restrict vertical movement during UVR exposures. This ensured that the animals remained horizontal during the irradiation procedure to maximize dorsal exposures, while the animals were able to move freely.
Two light sources were used for UV irradiation: a Philips CLEO Natural 62W-R or 100W-R solar simulator (Philips, Eindhoven, The Netherlands); both emit UVR with spectra and intensities similar to natural sunlight (UVA/UVB 23:1) (see supplementary Figure 1S , available at Mutagenesis Online). Incident radiation intensity was monitored with a calibrated radiometer (UVX with 36 sensor for the UVA wavelength range; UVP, San Gabriel, California, USA). The intensity of the lamp was measured just before the start of exposure and the exposure time was calculated using the following formula:
Two irradiation modalities were used. A short irradiation protocol where animals were irradiated 3 h after dosing with 1.5-2.0 mW/cm 2 for $30 min to give an average total dose of 2.6 J/cm 2 UV (in preliminary studies, rats were irradiated with 1.3, 2.6 or 3.9 J/cm 2 UV). A dose of 0.6 J/cm 2 UV was equivalent to one minimal erythema dose, which is the average minimal dose that caused just perceptible erythema in naïve skin of human Caucasians at 24 h after irradiation (20) . In subsequent studies, a lower intensity (0.7-1.0 mW/ cm 2 ) but extended irradiation protocol was implemented where animals were irradiated 30 min after dosing for $3 h to give a total dose of 7.8 J/cm 2 UV. With both irradiation modalities, UVR exposure times were corrected to account for reflection by the grid (factor 0.8).
Clinical signs and toxicology parameters Animals were observed daily for clinical signs, with special attention to dorsal skin, eyes, ears and paws. Body weight was measured just before the start of the study and just before sacrifice. Dermal erythema was measured daily using a mexameter MX16 (Courage & Khazaka Electronic, Köln, Germany) placed at three different sites on the exposed dorsal region of each animal. Mean erythema values were calculated for three measurements per animal per day. Transepidermal water loss (TEWL) was measured just before sacrifice using a tewameter TM 210 (Courage & Khazaka Electronic).
Animal necropsy and skin collection Animals were sacrificed by CO 2 /O 2 anaesthesia and decapitation, generally 72 h (AE3 h) after treatment unless otherwise stated. Prior to necropsy, the ventral areas were shaved along with dorsal to remove as much fur as possible. The ventral skin was used for intra-animal comparison with dorsal skin to determine whether ventral skin samples could serve as non-irradiated internal controls. Skin samples were prepared for MN analysis and/or histopathological assessments as required.
Skin micronucleus assay
Epidermal cell isolation. Epidermal skin cells (SCs) were isolated using the method developed by Nishikawa et al. (18, 19) , with minor modifications. Briefly, sections of skin were dissected and cut into pieces of $3 Â 4 cm and placed (epidermal side up) in a Petri dish containing gauze soaked in PBS and refrigerated ($4°C) until further processing. Subcutaneous tissue was removed, the skin pieces were sliced into small strips, using a scalpel blade and rinsed in 10 ml PBS and then immersed immediately in 10 ml 0.02% (v/v) EDTA/PBS solution at room temperature for 10 min. The skin strips were transferred into a Petri dish containing 10 ml 0.25% trypsin solution (epidermal side up) and refrigerated ($4°C) overnight for 15 h (AE2 h).
The following day, skin pieces were rinsed and the epidermis was peeled from the dermis and incubated in MEM supplemented with 10% FCS to obtain A. A. Reus et al.
single cells in suspension. Cell suspensions were subsequently filtered, centrifuged and incubated in 75 mM KCl solution. Finally, cell suspensions were fixed with a mixture of ethanol-glacial acetic acid and stored in a mixture of methanol-glacial acetic acid.
Slide preparation and staining for micronucleus assessment. Cell suspensions were centrifuged at 200 g for 5 min and the supernatant was removed. Cells were resuspended in an appropriate amount of fresh fixative (until a milky suspension was achieved). Slides were prepared by gently spreading of $100 ll of the fixed cell suspensions onto two glass slides, which were then air dried. Slides were stained with Giemsa (dermal application studies) or acridine orange (oral gavage studies) and mounted using standard methods.
Slide scoring. Prior to analysis, slides were coded to prevent operator bias. Where possible, a minimum of 2000 epidermal SCs per animal were analysed for the presence of micronuclei (MN), according to the criteria of Countryman and Heddle (21) . The quality of the fixed cell preparations was judged prior to slide scoring. If an excess of fragmented nuclei, cellular debris and/or absence of cytoplasm was observed, the slide was considered not analyzable and was discarded.
Statistical analysis
The number of micronucleated SCs (MNSC) per treatment group is presented as mean AE SD (in Tables I and II) or SEM (in Figures 1, 3 , 4 and 6). Induction factors were calculated in dorsal skin samples according to the following formula: number of MNSC in treated skin/number of MNSC in control skin.
Statistical differences between treated animal groups and vehicle controls were evaluated with the Dunnett's test and probability values of P , 0.05 (one tailed) were considered statistically significant. In addition, a comparison of dorsal and ventral MNSC frequencies was made.
Development and optimization studies using 8-MOP
Skin sampling time. The optimum sampling time for maximal MN induction in skin was determined following treatment with 8-MOP [0.9 lg/cm 2 painted directly onto skin or 200 mg/kg bw per os (p.o.)] and UV irradiation. Briefly, SD rats (males aged 8-10 weeks, typically five per group) were irradiated with 1.5-2.0 mW/cm 2 for $30 min to give a total dose of 2.6 J/cm 2 UV, as described above. Animals were killed 48 h, (dermal treatment only), 72 and 96 h (dermal and oral treatment) and 120 h (dermal treatment only) AE 3 h after UV irradiation and skin samples were prepared and analysed for MN induction as described above.
Selection of UV dose. A short irradiation protocol (total dose 1.3, 2.6 and 3.9 J/ cm 2 UV) and extended irradiation protocol (total dose of 7.8 J/cm 2 UV) were evaluated (see above) and MN induction in skin was determined in various rat strains, including SD rats. Briefly, rats (males aged 8-10 weeks, typically five per group) were treated with vehicle (50% aqueous ethanol for dermal treatment and corn oil for oral treatment), irradiated as described above and killed 72 AE 3 h later. Irradiated dorsal and non-irradiated ventral skin samples (oral treatment only) were prepared and analysed for MN induction as described above.
Skin micronucleus assays. Animals (males aged 8-10 weeks, typically in groups of three to five per cage) were treated dermally with varying doses of 8-MOP (0.03-0.9 lg/cm 2 ) or vehicle (50% aqueous ethanol) or orally with varying doses of 8-MOP (10-400 mg/kg bw p.o.) or vehicle (corn oil) and irradiated as described above using either the short or the extended irradiation protocols. Non-irradiated treatment groups were invariably included. Irradiated dorsal and non-irradiated ventral skin samples were obtained at necropsy, 72 AE 3 h after dosing, and analysed for MN induction as described above.
Kinetics study with 8-MOP. Figure 2S is available at Mutagenesis Online), with a specific activity of 44.22 mCi/mmol, and unlabelled 8-MOP. The animals were treated by gavage once with 200 mg/ kg bw 8-MOP; a dose corresponding to $300 lCi/kg bw. Animals were sacrificed by CO 2 /O 2 anaesthesia and exsanguination at 1, 2, 3, 4, 5, 8 and 24 h after treatment and various tissues were collected for analysis, including skin. Blood was collected from the abdominal aorta into heparinized tubes and plasma samples were prepared by centrifugation. Radioactivity of tissues and plasma was determined by liquid scintillation counting for calculation of the mean parent compound equivalents. Additional information with regards the procedure is provided in the supplementary data (available at Mutagenesis Online).
Histopathology. At necropsy, small pieces of dorsal and/or ventral skin were fixed in 4% buffered formaldehyde, embedded in paraffin and sections were for prepared for slide analysis. Slides were stained with haematoxylin and eosin for histological examination using standard methodology.
In addition, SC samples isolated for MN slide analysis were characterized histopathologically using various cell-specific biomarkers, such as anticytokeratin (Dako, Glostrup, Denmark; clone AE1/AE3) and anti-rat CD68 (Abcam, Cambridge, MD; clone ED1), to confirm the identity of the cells assessed for MN induction. Methodology is provided in supplementary data (available at Mutagenesis Online).
Results
Skin sampling time
The optimum sampling time point for maximal MN induction was determined following dermal treatment with 8-MOP (0.9 lg/cm 2 ) or vehicle (50% aqueous ethanol) and oral treatment with 8-MOP (200 mg/kg bw p.o) or vehicle (corn oil), followed by UV irradiation using the short irradiation protocol (total dose of 2.6 J/cm 2 UV). Skin samples were analysed for MN induction at various time points (48-120 h) following UV irradiation. Baseline MN frequencies at 72 h in irradiated dorsal rat skin ranged from 1 to 4, with a mean (AESD) of 2.8 AE 1.1 (n 5 5 animals) after dermal application of vehicle, and from 2 to 4, with a mean (AESD) of 2.8 AE 0.8 (n 5 5 animals) after oral treatment with vehicle. Following irradiation, there were small time-dependent increases in skin MN frequencies after dermal application of 8-MOP with maximal induction (3.9-fold) at 72 h (data not shown). Treatment with 8-MOP orally also resulted in time-dependent increases in skin MN frequencies following irradiation; again, maximal induction (4.1-fold) was observed at 72 h with some interindividual animal variation across the dose range ( Figure 1 ). Examples of MN in epidermal cells from animals either dermally or orally exposed to 8-MOP are shown in Figure 2 . There was no induction in MN frequencies in dorsal skin of SD rats observed in the absence of UV irradiation.
Selection of UV dose MN frequencies in dorsal skin of vehicle-treated animals were generally increased by 1.3, 2.6 and 3.9 J/cm 2 UV compared to non-irradiated control skin, but the increase was not dose related, was slight, and was somewhat variable (data not Fig. 1 . Time course of incidence of MNSC per 2000 SC in SD rats after oral treatment with 8-MOP (200 mg/kg bw) and UV irradiation using the short irradiation protocol (total dose 2.6 J/cm 2 UV). Animals were sacrificed at different time points following treatment and results are compared to vehicle control (sampled at 48 h). Open symbols are raw animal data (n 5 5 rats per group) and solid symbols represent group means AE SEM. * P , 0.05.
In vivo skin photomicronucleus assay shown). For example, in three separate studies using the short irradiation protocol (total dose 2.6 J/cm 2 UV), the frequency of MN in irradiated dorsal rat skin ranged from 0 to 4 with a mean (AESD) of 2.4 AE 0.7. This compared with a mean frequency of MN in non-irradiated ventral rat skin of 2.1 AE 0.8 (range 0-5) and 2.7 AE 0.6 (range 2-3) in dorsal skin from non-irradiated animals (Table I) . When the extended irradiation protocol was used (total dose 7.8 J/cm 2 UV), MN frequencies in dorsal skin of vehicle-treated animals were also slightly increased compared to non-irradiated control skin. Again, these increases were generally slight (i.e. MNSC frequency of 5.4 AE 1.5 (mean AE SD) in irradiated controls compared with 4.6 AE 0.5 in dorsal skin of non-irradiated controls, respectively) and interanimal values were somewhat variable in both irradiated controls (range 2-12) and non-irradiated controls (range 1-11), respectively. There was very little difference in MNSC frequencies between the ventral (non-irradiated) skin and the dorsal (irradiated) skin of the vehicle control group, suggesting that the latter might provide a useful internal negative control for the assay (Figure 3 ).
Photomicronucleus assay optimization using 8-MOP Clinical signs. Irrespective of the treatment or irradiation protocol used, all animal generally lie prone and remained dormant during the irradiation procedure. There were no adverse clinical signs observed in non-irradiated animals or irradiated vehicle control animal groups up to 3 days after treatment. Clinical signs were observed in all 8-MOP-treated animals following UV irradiation using both the short irradiation protocol (total dose 2.6 J/cm 2 UV) and the extended irradiation protocols (total dose 7.8 J/cm 2 UV). Clinical signs, including skin erythema, skin oedema (particularly ears and sometimes paws), discrete skin ulceration (dorsal skin) and ophthalmologic effects (corneal opacity), were observed and these are consistent with known 8-MOP phototoxicity. Their onset and severity were dose dependent and a record of the clinical signs observed is reported in supplementary Table  1S (available at Mutagenesis Online).
Phototoxicity assessments following 8-MOP treatment
Dermal erythema score, either determined using a mexameter or observed visually, in dorsal skin of irradiated 8-MOP-treated animals demonstrated dose-and time-related increases compared with dorsal skin of irradiated vehicle-treated animals. TEWL of dorsal skin of irradiated 8-MOP-treated animals also demonstrated an increase compared to the dorsal skin of irradiated vehicle-treated animals (supplementary Table 1S is available at Mutagenesis Online). Data from ventral (non-irradiated) skin samples. * P , 0.05. Fig. 3 . Incidence of MNSC in SD rats following UV irradiation using the extended irradiation protocol (total dose 7.8 J/cm 2 UV). Data are presented for dorsal skin (i.e. exposed skin samples) and ventral skin (i.e. nonexposed skin samples) for individual animals. Open symbols are raw animal data (square: experiment 1, circle: experiment 2, triangle: experiment 3 and diamond: experiment 4). Solid symbols represent group means AE SEM.
treated with increasing doses of 8-MOP (100, 200 and 400 mg/kg bw p.o.) to determine a dose, which would result in a minimum 3-to 5-fold increase in MN induction after UV irradiation dose (2.6 J/ cm 2 UV) with an acceptable phototoxicity profile. Epidermal MN frequencies demonstrated statistically significant (P , 0.05) increases at all 8-MOP doses compared to the irradiated vehicle control group (Figure 4) . The maximum increase in MNSC frequency was observed at 200 mg/kg bw (6.0-fold) and the MNSC frequency appeared to plateau at higher doses (400 mg/kg bw 8-MOP). At the highest dose (400 mg/kg bw 8-MOP), increased nuclear fragmentation and cellular debris were observed compared to lower doses, though the slides were still considered analyzable. Even at the lowest dose (100 mg/kg bw 8-MOP), there was a 4.6-fold increase compared with irradiated nontreated controls. The MNSC incidence in ventral non-irradiated skin of 8-MOP-treated animals was comparable to the non-irradiated and irradiated vehicle control groups (frequency range 0-4 MNSC per 2000 SC). Therefore, a dose of 200 mg/kg bw 8-MOP, using the short irradiation modality, was selected for further investigation.
8-MOP kinetics
In the rat, the pharmacokinetics of 8-MOP have been previously reported in animals dosed orally with 10 mg/kg bw and maximum plasma and skin levels of 8-MOP were observed between 2.5 and 3.5 h (22, 23) . In order to characterize 8-MOP exposure at higher dose levels, a pharmacokinetics study with 200 mg/kg bw 8-MOP in the absence of UV irradiation was performed to confirm the bioavailability of 8-MOP and to define the optimum time point for UV irradiation, i.e. the time point of maximum 8-MOP levels in the skin. The results showed that plasma levels of 8-MOP were biphasic with an initial peak at 2 h after dosing in plasma followed by a slight dip and then further increases (,2-fold) from 5 h onwards. The 8-MOP profile was similar in dorsal skin, although the initial peak was observed at 3 h and then increased again ($3-fold) from 5 h onwards ( Figure 5 ), but the standard deviation at this time point was relatively high.
Analysis of the stomach and gut showed incomplete absorption of 8-MOP with .50% of the dose retained in the digestive tract at 24 h, indicating that saturation had occurred. A comparison of other organs showed the highest concentration of radiolabelled material in kidney, adrenals and liver followed by the other organs (supplementary Figure 3S is available at Mutagenesis Online).
Reproducibility of skin photomicronucleus assay
The reproducibility of the short irradiation protocol (total dose 2.6 J/cm 2 UV within 30 min, 3 h after oral dosing of 200 mg/kg bw 8-MOP) was determined in four independent experiments. MN incidence in dorsal skin of 8-MOP-treated animals was significantly increased compared to the irradiated vehicle control group up to a maximum of 16.3 MNSC per 2000 SC ( Table I ). The mean induction factor was 5.8 (ranging from 4.1 to 7.3) and the overall reproducibility of the response was consistent, with low standard deviations.
Titration studies with 8-MOP in the skin photomicronucleus assay Further titration of the 8-MOP dose to 10 mg/kg bw 8-MOP was investigated, using an extended irradiation protocol with reduced irradiation intensity (total UV dose 7.8 J/cm 2 ), in order to eliminate phototoxic effects, particularly those observed in the eye (see below). The adoption of the extended irradiation modality, while reducing clinical signs of overt phototoxicity and improving slide quality, also resulted in a statistically significant (P , 0.05) increase in MNSC frequencies in dorsal skin following treatment with 8-MOP compared to the irradiated vehicle control group and 8-MOP-treated animals irradiated with the short irradiation protocol ( Figure 6 ).
The reproducibility of the extended irradiation protocol (total dose 7.8 J/cm 2 UV within $3 h, 30 min after oral dosing of 10 mg/kg bw 8-MOP) was determined in an additional four independent experiments (Table II) . MNSC incidence in dorsal skin of 8-MOP-treated animals was significantly increased compared to the irradiated vehicle control group. The maximum MNSC per 2000 SCs was 36 and was higher than the short UV exposure protocol. However, the MNSC incidence in dorsal skin of vehicle controls was also higher, Fig. 4 . Incidence of MNSC per 2000 SC after oral treatment with vehicle (corn oil) or 8-MOP followed by UV irradiation using the short irradiation protocol (total dose 2.6 J/cm 2 UV). Non-irradiated animals served as controls. Animals were sacrificed 72 h after treatment. Open symbols are raw animal data (n 5 3 rats per group) and solid symbols represent group means AE SEM. *P , 0.05. In vivo skin photomicronucleus assay resulting in an overall mean induction factor of 5.3 (range 4.0-6.0), which was lower than the short irradiation protocol. There was no difference in MNSC frequencies observed between the ventral (non-irradiated) skin and the dorsal (irradiated) skin in the vehicle control groups (supplementary Figure 4S is available at Mutagenesis Online).
Histopathology assessments
Histopathological evaluation of dorsal skin samples from rats treated with both the short irradiation protocol and 8-MOP (200 mg/kg bw) or the extended irradiation protocol and 8-MOP (10 mg/kg bw) showed evidence of phototoxicity as determined by epidermal degeneration/necrosis and dermal neutrophilic infiltration. Mild epidermal degeneration/necrosis was characterized by either or all of the following: epidermal spongiosis and hydropic degeneration, serocellular crusts and subcorneal clefts and pustules (Figure 6 ). At moderate severity grade, epithelial erosions were also present. Dermal neutrophilic infiltration was characterized by focal/multifocal (minimal) to diffuse (mild) infiltration of small neutrophilic infiltrates in the superficial dermis ( Figure 7) . Overall, the incidence and/or severity of histopathological findings were greater in rats treated with the short irradiation protocol and high 8-MOP dose compared to the extended irradiation protocol and lower 8-MOP dose. No test article-related microscopic findings were observed in the (non-irradiated) ventral skin.
Phototoxic effects were also observed in the eye. Ophthalmoscopic and slit lamp biomicroscopic examination confirmed corneal opacification and reddening of the conjunctiva in a significant proportion of animals treated with 8-MOP. These changes were consistent with histopathological findings of degeneration/inflammation in the cornea and anterior uvea and degeneration/necrosis of lens epithelial cells (data not shown). One advantage of titration of the 8-MOP dose from 200 mg/kg used with the short irradiation protocol to 10 mg/kg using the extended irradiation protocol was a significant reduction in both the frequency and the severity of phototoxic effects in the eye.
Immunocytochemical staining and qualitative examination of rat skin preparations used in the micronucleus assay, for cytokeratin (clone AE1/AE3), CD68, CD68 (clone ED1) and vimentin, confirmed that the large majority of cells were of epidermal origin (positive-specific cytoplasmic and nuclear cytokeratin staining and morphology consistent with epidermal keratinocytes; Figure 8 ). No cells showed specific positive staining for CD68 (macrophage marker) or for vimentin (mesenchymal origin). Appropriate tissue controls were positive for these primary antibodies (data not shown). In addition, neutrophils were only very rarely observed in the SC preparations. Therefore, treatment with 8-MOP did not significantly alter the composition of the cell preparations, despite evidence for focal inflammatory infiltrates in skin sections (see above and Figure 7 ).
Discussion
The present paper describes the development of an in vivo photoMNT in epidermal SCs of SD rats in order to fill a gap in the current photosafety testing strategy, i.e. between in vitro photogenotoxicity testing and in vivo photocarcinogenicity studies. Several a priori decisions on study design were made before experimental investigations commenced. These included decisions on animal species and strain, selection of the reference positive control (8-MOP), choice of default route of exposure and the parameter for genotoxicity assessment (MN induction in epidermal cells). The choice of animal species and strain was based on the premise that many other toxicological and kinetic parameters are determined in rat and that by and large, the rat is used as the primary species for genotoxicity assessment in the pharmaceutical industry. SD rats were selected because of in-house experience with this strain. The reference positive control for photogenotoxicity, 8-MOP, was selected because it is a potent photoclastogen and because treatment with 8-MOP and concomitant UV exposure is associated with higher rates of skin cancer in rats (23-25) and humans (26) . In other words, 8-MOP is Fig. 6 . Incidence of MNSC per 2000 SC after oral treatment with vehicle (corn oil) or 8-MOP (10 mg/kg bw) followed by UV irradiation using both the short and the extended irradiation protocols (total dose 2.6 and 7.8 J/cm 2 UV, respectively). Animals were sacrificed 72 h after treatment. Data are mean AE SEM. The incidence of MNSC was determined in 2000 SC after oral treatment with vehicle (corn oil) or 8-MOP (10 mg/kg) followed by UV irradiation using the extended irradiation protocol (total dose 7.8 J/cm 2 UV) in four independent studies Animals were sacrificed 72 h after treatment. Data represent group means (n 5 5 AE SD). ND, not determined. In vivo skin photomicronucleus assay a well-characterized photoclastogen and photocarcinogen. Besides the dermal route of exposure, compounds may reach the skin and/or eyes via systemic exposure and may subsequently provoke photo(geno)toxic effects. Therefore, both dermal and oral 8-MOP exposures were investigated initially, but as most pharmaceuticals are generally administered orally, it was decided to focus on oral exposure as a default route of administration. Finally, MN induction was selected as a genotoxic endpoint because MN represents a robust biomarker of genetic damage and MN induction is clearly associated with cancer development (27) . Therefore, we postulated that MN induction in epidermal SCs would serve as a useful biomarker of potential photocarcinogenic liability, i.e. in the target organ for skin cancer and thus provide a suitable parameter for early screening.
The experimental investigations described in the present study have been used to shape the development and characterization of the in vivo photoMNT in rat epidermal SCs and inform the final study design. Criteria evaluated included selection of UV irradiation modality and dose, optimization of dorsal skin sampling procedures and also the harvest time after irradiation for maximal MN frequencies. Results showed that maximal MN induction occurred 72 h after 8-MOP treatment and UV irradiation and therefore, this defines the optimum time point for cell isolation in the assay. These results were in agreement with preliminary data using dermal application of 8-MOP and also confirm data in other rat strains obtained previously in our laboratory (28) . These data are also in agreement with results of studies conducted by Nishikawa et al. (18, 19) and Hara et al. (16) in rat and mouse skin after topical application of genotoxic compounds.
Qualitative immunohistochemical assessment confirmed that the SC preparations from control and 8-MOP-treated animals were highly enriched for cytokeratin-positive keratinocytes. Cytokeratin immunopositivity is usually cytoplasmic, as shown in the immunostained skin section (Figure 8 ). In the SC preparations examined, specific nuclear immunostaining was also observed for cytokeratin. The presence of specific nuclear staining is considered to be related to the preparation of the SCs.
The initial doses of 8-MOP were selected based on oral LD 50 data in the rat in the absence of UV irradiation, i.e. 791 mg/kg bw (29) plus data from the National Toxicology Program (30) showing that doses .400 mg/kg bw resulted in death in F344 rats within 5 days of treatment. Therefore, doses of 100, 200 and mg/kg bw (i.e. 1/8LD 50 , 1/4LD 50 and 1/2LD 50 ) were initially selected for investigation of MN induction in rat epidermal skin as an index of photoclastogenicity. Results showed that the frequency of micronucleated SCs reached a plateau at doses of 200 mg/kg bw and above using the short irradiation protocol, i.e. where animals were irradiated 3 h after dosing with 1.5-2.0 mW/cm 2 for $30 min to give an average total dose of 2.6 J/cm 2 UV. Therefore, an oral dose of 200 mg/kg bw 8-MOP was selected for further investigation. The results of four independent studies (Table 1) showed that oral treatment of SD rats with 200 mg/kg bw 8-MOP produced on average a $6-fold induction in MN frequency in epidermal cells from dorsally irradiated skin compared with irradiated vehicle controls. These data were highly reproducible and confirmed 8-MOP photoclastogenicity in UV-exposed skin of rats. Similar 8-MOP doses have been reported to be positive in the photocomet assay in rodents (14, 15) . In addition to photogenotoxicity, the phototoxic effects of 8-MOP treatment were evaluated in the same animals. Erythema score, as determined by a mexameter, corresponded well with visual observations and also correlated with 8-MOP dose and UV exposure, unlike TEWL measurements. Histopathological findings from examination of skin sections also correlated well with 8-MOP treatment and UV exposure. Therefore, both photogenotoxic with phototoxic effects were apparent in SD rats dosed with 200 mg/kg bw 8-MOP using the short irradiation protocol.
Toxicokinetic analysis of ( 14 C)-8-MOP at the 200 mg/kg bw dose in SD rats (in the absence of UV irradiation) confirmed plasma and skin exposure to radiolabelled material and suggested a T max of 2 and 3 h, respectively. Radiolabelled material was also present in various organs and tissues (see supplementary Figure 4S , available at Mutagenesis Online) with the majority remaining in the gastrointestinal tract 24 h after dosing, indicating incomplete absorption. In contrast, published kinetic data using lower doses of 8-MOP (10 mg/kg bw) have shown that oral administration in the rat also results in plasma and skin exposures with a T max of 2.5 and 3.5 h, respectively, but a significant retention in the gastrointestinal tract was not mentioned (22, 23) . Clearly, pharmacokinetic data can provide information on C max and T max in the skin, which is helpful when defining the optimum time point for UV exposure to induce maximal MN induction. Therefore, using the short irradiation protocol where animals were irradiated 3 h after dosing with 1.5-2.0 mW/cm 2 for $30 min to give an average total dose of 2.6 J/cm 2 UV ensured irradiation near the T max for 8-MOP treatment in SD rats.
The UV dose administered using the short irradiation protocol demonstrated slight (but nonsignificant) increases in MN formation over non-irradiated control skin (Figure 2 ). This is consistent with the notion that animals received a biologically relevant UV dose. The lamps used simulated solar radiation with combined UVA and UVB radiation components (ratio 23:1). Simulated solar radiation provides a more biologically relevant and appropriate UV exposure compared with UVA alone. One of the disadvantages of the short irradiation protocol, however, was the relatively high incidence of adverse clinical signs and phototoxic effects seen with 8-MOP (particularly those in the eye). Another disadvantage of the short irradiation protocol is the assumption of T max within 3-3.5 h after oral dosing, which is not appropriate for compounds with other kinetic profiles. Therefore, another irradiation modality was investigated, consisting of an extended irradiation protocol with lower intensity (0.7-1.0 mW/cm 2 ) where animals were irradiated 30 min after dosing for $3 h to give a total dose of 7.8 J/cm 2 UV. The latter irradiation modality prolongs UV exposure in the rat over a period, which would be anticipated to include the T max for most orally administered compounds, thereby maximizing photoactivation potential. In addition, the reduction in UV irradiation intensity, together with 8-MOP dose titration, was used to minimize phototoxic effects associated using the short irradiation protocol and 8-MOP treatment. This extended irradiation protocol was based on the one used in mice by Itoh et al. (17) .
In addition, the 8-MOP dose was titrated down from 200 to 10 mg/kg bw (data not shown). The results of four independent studies showed that oral treatment in SD rats with 10 mg/kg 8-MOP produced on average a $5-fold induction in MN frequency in epidermal cells from dorsally irradiated skin compared with irradiated vehicle controls (Table 2) . Again, these data were highly reproducible and confirmed 8-MOP photoclastogenicity in the skin of rats irradiated over a period spanning the C max and T max at this dose (22, 23) . Interestingly, there was no increase in MN frequency in epidermal cells from nonirradiated ventral skin, confirming the photogenotoxic effect in dorsal skin and suggesting that ventral skin may serve as an internal negative control in the in vivo rat skin photoMNT. Although the average MN induction factor with the short irradiation protocol tended to be higher compared to the extended irradiation protocol, the mean fold induction factors (6.3-fold versus 5.3-fold, respectively) were rather similar, considering the difference in 8-MOP dose (200 versus 10 mg/kg bw) and irradiation intensity (1.5-2.0 vs. 0.7-1.0 W/ cm 2 , respectively). Short intense UV exposures many induce a relatively high amount of DNA damage and repair kinetics will start shortly after exposure. Extended but less intense UV exposures will result in mixed kinetics of formation of DNA damage and repair during formation. However, epidermal cells were not harvested immediately but 72 h after irradiation, which means that there was sufficient time for DNA repair to occur. These data suggest that there may be an upper limit for photoactivation of 8-MOP in vivo or a limit for the potential for photoactivated material to be converted into DNA damage. Further research will be required to understand these complex relationships.
One of the advantages of the extended irradiation protocol will be to accommodate more readily those compounds with unknown skin exposure kinetics. The refinement in dose and UV modality also limited the adverse clinical signs seen with 8-MOP while retaining photoclastogenic activity. Therefore, the extended irradiation protocol represents the preferred default study design. The reproducibility of the photoclastogenic response suggests that the use of 8-MOP as a positive control may provide a gold standard for comparison with other compounds as development of the assay progresses. It is therefore of interest to note that robust photoclastogenicity with 8-MOP treatment was seen with only limited phototoxicity. In addition, it is clear that the current assay design is amenable to (parallel) evaluation of phototoxicity, providing the opportunity to evaluate both endpoints in the same animal. Nevertheless, it will be interesting to explore the relationship between photoclastogenicity and phototoxicty as development progresses. Therefore, daily observation of clinical signs and examination of histopathology at necropsy will be included in future studies.
Although the total UV doses used in the current studies were lower than those previously used in the photocomet assay in rats and mice (14, 15) or photoMNTin mice (16, 17) , which typically ranged from 7 to 23.6 J/cm 2 UV, given the differences in irradiation source, UVA/UVB ratio, UV spectrum and UV dose rate, it is difficult to compare between these studies. Nevertheless, it is known that UVB radiation has a higher potency to induce DNA damage compared to UVA (3) and the radiation emitted by the lamps used in the present study contained a relatively high proportion of UVB. Nevertheless, for the reasons stated above, we believe that solar-simulated radiation provides the most appropriate UV source for evaluating photo(geno)toxic liabilities.
The use of rats for the in vivo skin photoMNT has several advantages compared to mice. First, in the pharmaceutical industry, the rat is often a default species for nonclinical safety assessment and many other toxicological and kinetic parameters are determined in rats. These data can be helpful with dose selection and with establishing maximum levels in the skin to define the optimum time point for irradiation. Second, the dorsal skin of rats can easily be shaven prior to the treatment, whereas this is more difficult with mice. Consequently, in the rat assay, normal strains can easily be used, but genetically modified hairless mice are often used in the mouse assay. Finally, the dorsal skin of rats is larger than mice, ensuring a more equal distribution of UV exposure on the skin. For these reasons, rats were the preferred species for developing the in vivo skin photoMNT.
The results of the present study indicate that the in vivo rat skin photoMNT can detect photoclastogenicity following treatment with the known photogenotoxin and photocarcinogen, 8-MOP. Given the association between MN induction and cancer, the assay may also provide a promising tool for the early detection of photocarcinogenesis and help bridge the gap in the existing photosafety testing paradigm. Further research is ongoing to investigate the reproducibility and predictive capacity of the in vivo rat skin photoMNT using FQs as a chemical class with varying degrees of photosafety liability. In addition, the portability of the assay will be investigated in our respective laboratories [Netherlands Organisation for Applied Scientific Research (TNO) and GlaxoSmithKline]. The results of these studies will be presented in the near future.
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